MOTS-c Peptide Protects Liver from Acetaminophen Overdose Damage
Background
Acetaminophen (APAP) overdose is a leading cause of acute liver failure worldwide, characterized by severe hepatocyte necrosis and inflammation. Current treatments are limited, highlighting an urgent need for novel therapeutic strategies to mitigate APAP-induced liver injury. This study specifically addresses the knowledge gap regarding potential protective agents that can modulate cellular stress pathways in the liver following APAP toxicity.
Results
The study found that MOTS-c significantly attenuated APAP-induced liver damage, as evidenced by reduced serum liver enzyme levels. Specifically, MOTS-c treatment led to a 43% reduction in serum ALT and a 38% reduction in AST levels compared to the APAP-only group at 24 hours (p<0.01). Histopathological analysis revealed a 65% decrease in necrotic areas in the livers of MOTS-c-treated mice. Furthermore, MOTS-c inhibited the activation of the MAPK signaling pathway, showing a 2.5-fold decrease in phosphorylated ERK1/2 and JNK proteins. This suggests a crucial role for MOTS-c in modulating cellular stress responses. > The most important finding was that MOTS-c treatment significantly reduced APAP-induced hepatocyte apoptosis by 55% and inflammatory cytokine production (e.g., TNF-α and IL-6) by over 40% compared to controls, indicating broad protective effects.
Why It Matters
This research highlights MOTS-c as a promising therapeutic candidate for preventing or treating acute liver injury caused by acetaminophen overdose. Its ability to modulate the MAPK signaling pathway and reduce both necrosis and inflammation suggests a multifaceted protective mechanism. Given the significant burden of APAP-induced liver failure, MOTS-c could potentially be developed into a novel pharmacological intervention to improve patient outcomes. Future steps should involve further mechanistic studies and progression towards human clinical trials, potentially starting with Phase I safety assessments.